Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04248153 · ClinicalTrials.gov registry record · Phase 2
Optimal Timing of BR55 CEUS of the Ovaries
A Phase 2 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04248153: Clinical Trial Phase 2 study, sponsored by Bracco Diagnostics.
NCT04248153 is a Phase 2 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04248153, a Phase 2 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.
Primary Outcome
Number of participants who received the contrast agent and experienced an adverse event.
Interventions
- DRUG BR55
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Why NCT04248153 stopped before completion
NCT04248153 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which BR55 is the first listed.
NCT04248153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04248153 about?
NCT04248153 is a clinical study titled "Optimal Timing of BR55 CEUS of the Ovaries". This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familia...
What is the current status of trial NCT04248153?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-10-14. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04248153?
The interventions under investigation include: BR55 (DRUG).
Who is sponsoring clinical trial NCT04248153?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04248153's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI